|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004561,
umls-concept:C0017262,
umls-concept:C0024314,
umls-concept:C0030705,
umls-concept:C0032659,
umls-concept:C0054946,
umls-concept:C0178587,
umls-concept:C0185117,
umls-concept:C0205191,
umls-concept:C0431085,
umls-concept:C2911684
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-11-9
|
|
pubmed:abstractText |
Rituximab is being used successfully in the treatment of patients with chronic B-cell lymphoproliferative diseases. The success of treatment by rituximab is influenced, among other factors, by the antigen density on tumor cells. Therefore, the authors analyzed and compared the densities of the CD20 antigen in patients with chronic lymphoproliferative diseases.
|
|
pubmed:language |
cze
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0008-7335
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
145
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
712-6; discussion 716-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17091727-Aged,
pubmed-meshheading:17091727-Antigens, CD20,
pubmed-meshheading:17091727-B-Lymphocytes,
pubmed-meshheading:17091727-Female,
pubmed-meshheading:17091727-Flow Cytometry,
pubmed-meshheading:17091727-Humans,
pubmed-meshheading:17091727-Leukemia, B-Cell,
pubmed-meshheading:17091727-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:17091727-Lymphoma, B-Cell,
pubmed-meshheading:17091727-Lymphoma, Mantle-Cell,
pubmed-meshheading:17091727-Male,
pubmed-meshheading:17091727-Middle Aged
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
[Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases].
|
|
pubmed:affiliation |
Laborator flow cytometrie a celulární terapie LF MU a FN, Brno. 43047@mail.muni.cz
|
|
pubmed:publicationType |
Journal Article,
English Abstract
|
